Phosphoinositides and Charcot-Marie-Tooth disease: New keys to old questions by Suter, U.
Visions & Reflections (Minireview)
Phosphoinositides and Charcot-Marie-Tooth disease:
New keys to old questions
U. Suter
Institute of Cell Biology, Department of Biology, ETH Zrich, ETH-Hçnggerberg, 8093 Zrich (Switzerland),
e-mail: usuter@cell.biol.ethz.ch
Received 19 August 2007; received after revision 3 October 2007; accepted 9 October 2007
Online First 29 October 2007
Abstract. Recent research into the genetic basis and
the molecular disease mechanisms of Charcot-Marie-
Tooth disease (CMT), also called hereditary motor
and sensory neuropathies, has highlighted phosphoi-
nositides,membrane-tethered phosphorylatedmetab-
olites of phosphatidylinositol, as key regulatory mol-
ecules in peripheral nerves in health and disease.
Enzymes that dephosphorylate the endosomal phos-
phoinositides phosphatidylinositol-3-phosphate and/
or phosphatidylinositol-3,5-biphosphate, and proteins
with binding domains for these phosphoinositides, are
mutated in subtypes of CMT. A hypothetical picture
emerges suggesting that the precise regulation of
phosphoinositide levels within neural cells, a process
in turn critical for the correct dynamics of proteins
binding to phosphoinositides, is a crucial bottleneck
for the accurate function of myelinated peripheral
nerves in both neurons and Schwann cells. The
underlying molecular and cellular mechanisms are
largely unknown. Some hypotheses are discussed in
this essay.
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Charcot-Marie Tooth disease (CMT) denotes a het-
erogeneous group of genetic diseases that affect
peripheral nerves, leading to pronounced muscular
atrophy and weakness of distal limbs. Based on
electrophysiological, neuropathological and genetic
data, it is thought that the initial causative damage due
to the mutation involves only the myelinating
Schwann cell in some disease subtypes. In others,
only motor and sensory neurons might be affected,
and in some cases, both cell typesmay be involved (for
an updated list of the genes and mutations involved in
CMT, see http://www.molgen.ua.ac.be/CMTMuta-
tions/default.cfm; for detailed information on the
different disease subtypes, consult http://www.neuro.-
wustl.edu/neuromuscular/time/hmsn.html; for sum-
maries of cellular and molecular disease mechanisms,
see reviews [1–4]).
Delineating the initial trigger for the disease and the
precise consequences at the cellular level are of
utmost importance for understanding the underlying
disease mechanisms and ultimately for development
of promising treatment strategies. In parallel, such
studies also provide considerable insights into the
biology of myelinated peripheral nerves. The approx-
imately two dozen genes identified today that lead to
different forms of CMT present a rich source of
proteins that are of eminent importance for the proper
function of peripheral nerves. Elucidating the precise
roles of these proteins and identifying potentially
crucial networks in which these proteins may act in
concert is a major challenge for the future. The main
topic of this article, membrane-bound phosphorylated
phosphatidylinositols (PI, or phosphoinositides) and
their regulators and binding partners, appear to be
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positioned right at the heart of such a critical node of a
regulatory signaling network [5].
The main cell types involved in peripheral nerves that
are primarily affected by the various mutant proteins
in CMT are very special cells in terms of their cell
biology. This notion relates particularly to the peculiar
structure of the cells and the tasks that they fulfill.
Many peripheral neurons have long axonal projec-
tions that may extend up to a meter to their targets, so
that these neurons face special cellular challengeswith
regard to building up and functionally maintaining
these elaborate structures. Besides some critical basic
issues of membrane and protein maintenance over
long distances, general axonal transport of organelles
and loaded vesicles must function efficiently in both
directions during development and in homeostasis.
Not surprisingly, based on the finding that distal
muscles are mainly affected in CMT and supportive
cell biological data, it has been suggested that
deficient axonal transport may be a key issue in
many forms of CMT [1]. Conversely, myelinating
Schwann cells have the formidable task of producing
and maintaining enormous amounts of proteins and
lipids in the multi-lamellar myelin sheath. In CMT, it
may still be a matter of debate how much of the
disease mechanism in the individual subtypes is
related to developmental alterations and how much
is due to pure neural degeneration after initially
normal development. Regardless of this uncertainty,
which will hopefully be resolved by careful analysis of
suitable animal models combined with patient data,
the special challenges of Schwann cells and neurons
remain. Throughout development, they have to gen-
erate bulk amounts of membranes in a highly coordi-
nated manner. Once the cells are fully differentiated
in the adult with little or no cellular turnover, both
neurons and myelinating Schwann cells still have to
metabolically maintain their proper structures and
functions. From a cell biological point of view, another
key issue in both nerve development andmaintenance
is ensuring accurate communication between the
different cell types that critically regulates the phys-
iology of neurons and Schwann cells in a bi-directional
fashion [6, 7]. On the molecular level, the regulatory
mechanisms involved include gene transcription,
classical signaling pathways, membrane production,
membrane and protein trafficking and function, and
cytoskeletal rearrangements. Phosphoinositides have
been implicated in many if not all of these crucial
cellular processes [5]. Thus, it comes as little surprise
given the complex cell biology of the cells involved
that disturbance of the phosphoinositide metabolism
is deleterious to the proper function of myelinated
nerves. On the other hand, one might have expected
that global alterations would not be compatible with
life, given the broad role of phosphoinositides in
different cell types. Is it only the complex require-
ments of myelinated peripheral nerves that make
them particularly vulnerable, or are there also other
possible explanations? To find potential answers to
this question, it is instructive to have a closer look at
the specific CMT-related proteins involved in phos-
phoinositide metabolism. One such group comprises
the enzymes that dephosphorylate phosphatidylinosi-
tol-3-phosphate (PI3P) and phosphatidylinositol-3,5-
biphosphate [PI(3,5)P2] [5, 8, 9]. These specific
phosphoinositides are found on the cytosolic side of
different categories of endosomes, and play major
functional roles in the complexmembrane system that
regulates intracellular trafficking of membranes and
proteins. PI3P is predominant on early endosomes and
serves as a specific address to target proteins with
PI3P-binding domains to these vesicles. There these
proteins, usually in the form of larger complexes, exert
their functions in various processes including mem-
brane fusions and signaling events. PI(3,5)P2 is
present in low levels in the late endosome/lysosome
compartments. Its function is not well understood in
mammalian cells, but might involve the control of
membrane recycling between lysosomes and late
endosomes.
The levels of different phosphoinositides are regulated
by a set of phosphoinositide kinases and phosphatases.
Myotubularin-related protein (MTMR)-2 dephos-
phorylates both PI3P and PI(3,5)P2 specifically at
the D3 position and is mutated in recessive CMT4B1
[3, 10]. MTMR2 belongs to a large family of rather
ubiquitously expressed proteins. The eight family
members with catalytic activity appear to share the
same substrate specificity with MTMR2, and many if
not all of the disease-associated MTMR2 mutations
lead to loss of enzymatic activitywhen assayed in vitro.
The six inactivemembers of theMTMR family tend to
form complexes with active MTMRs. The most
relevant interaction with regard to CMT is the
formation of a tetrameric complex between MTMR2
and MTMR13, since mutations in MTMR13 are
associated with recessive CMT4B2 [3, 10]. This form
of the disease is pathologically indistinguishable from
CMT4B1 and can be modeled in the mouse [11].
Within the MTMR2/MTMR13 complex the phospha-
tase activity of MTMR2 is enhanced by an order of
magnitude [12], consistent with the hypothesis that
this enzymatic activity is crucial for the function of
MTMR2 in myelinated peripheral nerves [13]. The
regulatory situationmight bemore complex, however,
since both MTMR2 and MTMR13 also contain
protein domains that bind to phosphoinositides. In
general, MTMR2 and MTMR13 are mainly cytoplas-
mic proteins, also in neurons and Schwann cells, but
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binding of MTMR2 and MTMR13 to intracellular
membranes has been shown in a heterologous cell
system [12]. Based on those data, a model has been
proposed in which MTMR2 and MTMR13 might be
present both as dimers and as heterotetramers within
a cell, but with different affinities for membranes
likely mediated by the phosphoinositide-binding do-
mains present in both proteins. It remains an open
question how such presumably fine-tuned bindings
may lead to changes in phosphoinositide composition
on endosomes and, as a potential consequence, to
altered localization of the MTMR complexes and
other binding proteins. What is clear, however, based
on elegantmouse genetic experiments is thatMTMR2
deficiency exclusively in Schwann cells is sufficient to
generate myelin outfoldings as seen in CMT4B1 and
CMT4B2 [14–16]. Such aberrant structures contain
redundant myelin membranes that originate during
late development ofmyelinating Schwann cellsmainly
at the paranodes and Schmidt-Lanterman incisures,
regions that contain Schwann cell cytoplasm with
endosomes and lysosomes. Paranodes and Schmidt-
Lanterman incisures are also thought to be the main
regions of the myelin sheath where addition and
turnover of myelin membranes and its protein com-
ponents occur. These findings, together with the
known functions of the phosphoinositide substrates
of MTMR2, suggest that MTMR2 is involved in the
regulation of membrane addition and/or remodeling.
Altered membrane trafficking, recycling, or impaired
degradation may lead to the observed phenotype. The
finding thatMTMR2 binds toDlg1/SAP97, a scaffold-
ing protein involved inmembrane biology in other cell
types, lends indirect support to this hypothesis [14].
Alternatively or concomitantly, classical signaling
pathways might also be altered by the changes in
phosphoinositide levels and contribute to the pheno-
type [17]. Taken together, the available data are
consistent with the hypothesis that phosphoinositides
and their regulators may control myelin growth in a
criticalmanner providing a potential key to the largely
unknownmolecular processes that govern howmyelin
membranes are added and degraded.
Recently, a second active phosphoinositide phospha-
tase called FIG4 (or Sac3) has been identified as the
culprit protein mutated in CMT4J [18, 19]. The initial
observations were made in a spontaneous mouse
mutant called the “pale tremormouse”, which shows a
syndrome that includes widespread central (CNS) and
peripheral (PNS) nervous system neurodegeneration.
Of special relevance to CMT, a major loss of sensory
neurons is evident during the neonatal period, while
other sensory neurons contain large cytosolic va-
cuoles, suggesting that this stage precedes cell death.
Mutant motor neurons develop morphologically sim-
ilar vacuoles at the age of 6 weeks. The number of
large myelinated axons is reduced, consistent with the
observed neuronal alterations. Considerably slowed
nerve conduction velocities indicate that alterations in
myelinated Schwann cells may also be involved. The
latter is supported by pathological findings in CMT4J
showing, besides prominent axonal loss, thinly myeli-
nated axons and signs of de- and remyelination.
Clinically, CMT4J patients are heavily affected, also
Figure 1. The upper part of the
figure shows a schematic cut-
away view of a myelinated pe-
ripheral nerve fiber. Proteins
known to cause CMT that are
directly connected with the phos-
phoinositide metabolism are in-
dicated. They are shown as being
expressed in both, neurons and
myelinating Schwann cells. This
is an assumption based on cir-
cumstantial evidence, with the
exception of MTMR2 and
MTMR13, and needs to be rigor-
ously assessed in future experi-
ments. The exact distribution of
endosomes containing PI3P and/
or PI(3,5)P2 in the myelinated
neuron/axon and in themyelinat-
ing Schwann cells is also not
worked out. Thus, only generic
endosomes are indicated in the
schema. In the lower part of the
figure, the general structure of
the phosphoinositide backbone
is shown together with the phos-
phorylation sites.
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by profound neuronal loss in the CNS, with complex
genetics. The known patients are compound-hetero-
zygous for FIG4, each carrying a null allele in
combination with a particular mutation, I41T, on the
other allele. This pointmutation affects FIG4 function
in yeast, where it causes a partial loss of function. On
themolecular level, FIG4 dephosphorylates PI(3,5)P2
at the D5 position, consistent with the observed
neuronal vacuoles that are most likely of late-endo-
somal-lysosomal nature in the FIG4 mutant [20].
One of the critical regulatory functions of phosphoi-
nositides is the recruitment of proteins that contain
phosphoinositide-binding modules, resulting in a
highly dynamic signaling system. As mentioned ear-
lier, the culprit genes in CMT4B1 (MTMR2) and
CMT4B2 (MTMR13), besides being phosphoinosi-
tide phosphatases or regulators thereof, also contain
phosphoinositide-binding motifs [9]. Recent work
revealed that other CMT-causing disease proteins
also contain such domains. Frabin/FGD4, an actin-
binding guanine nucleotide exchange factor (GEF)
for the RhoGTPase Cdc42 and mutated in CMT4H,
contains a FYVEdomain and two PHdomains, motifs
known to bind to phosphoinositides [21, 22]. Intrigu-
ingly, myelin outfoldings are the hallmark of CMT4H
as in CMT4B1/2, hinting towards potentially con-
nected disease mechanisms by a crucial interplay
between phosphoinositide-binding proteins and phos-
phoinositide modulators. Furthermore, dynamin2, a
large GTPase that plays a major role in the regulation
of membrane dynamics and trafficking by mediating
vesicle formation, is mutated in the dominant
CMTDIB in which loss of large caliber axons and
myelin deficiencies are the pathological features [23].
Most interestingly, the CMTDIB-causing mutations
are clustered in a phosphoinositide-binding PH do-
main, indicating another connection to phosphoinosi-
tides [24].
In summary, the current knowledge strongly suggests
that phosphoinositidemetabolism plays a key role in a
variety of CMT subtypes and in peripheral nerve
biology. These phospholipids seem to represent crit-
ical converging regulatory points due to the unique
cellular requirements of neurons and myelinating
Schwann cells. Many fine points need to be work out,
such as the exact contribution of phosphoinositide-
mediated signaling in neurons and Schwann cells, the
different forms and dynamics of the regulatory
mechanisms, and the contribution and influence of
other cellular mechanisms in the complex network of
the physiology of the cells. This will require the
elucidation of many different aspects of endosome
biology with regard to endocytosis, membrane recy-
cling, and the connected regulatory function of endo-
somes as critical platforms for controlling signal
transduction [25]. Likely feedback mechanisms and
quantitatively delicately balanced processes will have
to be dissected. Novel techniques, in particular with
regard to membrane dynamics of proteins and lipids,
and especially phosphoinositides, will have to be
developed in living cells [26].
One might argue that phosphoinositides have only
been implicated in relatively rare subtypes of CMT,
and that their general relevance for the more frequent
causes of the disease is questionable. I would make a
strong case for the theory that the proteins that are
mutated in CMTplay by definition a crucial role in the
complex biology of peripheral nerves, and that the
combined analysis of these proteins and their disease-
causing forms will eventually converge to a rather
coherent picture of the critical regulatory networks
involved. Knowing these networks in detail will be
beneficial for the understanding of each component
and the system of myelinated peripheral nerves as a
whole, and in this way contribute substantially to the
rational development of potential therapies for dis-
eases affecting the nerves as an integrated unit. To
leave the reader with a highly speculative thought in
this regard: Altered intracellular transport, biosyn-
thesis and/or degradation have been put forward as
potential disease mechanism in some of the most
common forms of CMT [2, 3, 27], in particular PMP22
duplications, which account for the majority of cases
[1, 28, 29].Many of these processes are under stringent
control of phosphoinositides and their regulators as
they are essential players in regulating the endosomal-
lysosomal system and autophagy. Maybe there are
more connections than obvious at first glace, both
related to myelinating cells as well as to neurons and
their axon.
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